In the GAUSS trial, 175 patients with relapsed indolent CD20+ DLBCL who responded to rituximab but developed progression were randomized to either a rituximab maintenance or obinutuzumab arm. This evidence concerns the gene MS4A1 and diffuse large B-cell lymphoma.